The upcoming webinar will delve into the advanced applications of Next Generation Flow™ in the analysis of Minimal Residual Disease (MRD) in Multiple Myeloma (MM). Dr. Juan Flores-Montero, a ...

Both of them right now rely on bone marrow testing: next-generation flow cytometry, which is an advanced flow cytometry to [provide a] more sensitive way of detection, or next-generation ...

Purpose Assessing measurable residual disease (MRD) has become standard with many tumors, but the clinical meaning of MRD in multiple myeloma (MM) remains uncertain, particularly when assessed by next ...

Clinical updates for August 2020 featured in Evidence-Based Oncology. MRD Should Be More Widely Used in Clinical Care of MM, Report Argues Advances in scientists' understanding of multiple myeloma ...

"Medical Journeys" chart a path each step of the way for physicians and patients and provide continual resources and support, ...

Bone Marrow Transplantation - Monitoring of minimal residual disease in multiple myeloma after allo-SCT: flow cytometry vs PCR-based techniques ...

If you have multiple myeloma, chances are good that it will return even after you’ve been in remission. Find out why and what to do when it happens.

Darzalex addition to VRd improved MRD negativity and PFS in transplant-ineligible multiple myeloma patients. The CEPHEUS trial showed a 50% increase in MRD negativity with Darzalex, consistent across ...

The reason is that myeloma infiltrates the bone marrow. Techniques for identifying minimal residual disease, like cytometry or next-generation massive sequencing, can detect bone marrow blood ...

The FDA appears receptive to the idea of using minimal residual disease to support accelerated approvals of new multiple myeloma drugs, even though it has some questions.

Assessing measurable residual disease (MRD) has become standard with many tumors, but the clinical meaning of MRD in multiple myeloma (MM) remains uncertain, particularly when assessed by ...